key: cord-0889961-lk4jmeuz
authors: Mullur, Jyotsna; Wang, Alberta; Feldweg, Anna
title: A fatal case of COVID-19 in a patient with common variable immunodeficiency
date: 2020-08-18
journal: Ann Allergy Asthma Immunol
DOI: 10.1016/j.anai.2020.08.017
sha: 07dafcd10ebc0b8a9570cf3a477f3b1edcb46fe7
doc_id: 889961
cord_uid: lk4jmeuz

nan

Common variable immunodeficiency (CVID) is a heterogenous group of primary 1 immunodeficiency syndromes characterized by hypogammaglobulinemia and impaired vaccine 2 responses. While immunodeficiency is described as a risk factor for COVID-19, there are few 3 data regarding CVID. Three recent reports describe mostly positive outcomes in CVID patients 4 who developed COVID-19 1-3 , with only one fatality 3 . All these patients had adequate IgG levels 5 at the time of COVID-19 diagnosis [1] [2] [3] . We present a case of a patient with a history of CVID and 6 severely low IgG levels due to a lapse in immune globulin replacement, who died of 7 complications related to COVID-19, despite receiving convalescent plasma and high-dose 8 intravenous immune globulin (IVIG). 9 The patient was a 42 year-old man with a longstanding history of asthma, morbid obesity, 10 and CVID characterized by recurrent sinopulmonary infections. He was previously on regular 11 monthly IVIG and reportedly stable. However, he had not received any IVIG within the last six 12 months due to insurance issues. He developed COVID-19 symptoms in May 2020 with a 13 positive nasopharyngeal polymerase chain reaction (PCR) swab for SARS-CoV-2. He was 14 initially quarantined at home for four days. However, he developed fevers and worsening 15 dyspnea, and was admitted to a community hospital. A chest CT showed multifocal pneumonia. 16 On hospital day 4, he was intubated due to worsening hypoxemia. On hospital day 5, he received 17 convalescent plasma and started remdesivir. On hospital day 6, vancomycin was started for 18 methicillin-resistant staphylococcus aureus (MRSA) cultured from sputum. He was subsequently 19 transferred to our facility for a higher level of care. 20 On transfer, his presentation was consistent with acute respiratory distress syndrome. 21 Notable laboratory results included IgG 117 mg/dL, IgA 10 mg/dL, undetectable IgM, ESR >130 22 mm/h, and CRP >300.0 mg/L. He had a white blood cell count of 8.27×10 3 /µL (76% neutrophils, 23 J o u r n a l P r e -p r o o f 8% lymphocytes, 5% monocytes, 1% eosinophils, 2% atypical lymphocytes, and 8% bands). 24 Ceftazidime was started for bacterial pneumonia. Meropenem was started for sinusitis after 25 culture of purulent nasal secretions grew extended-spectrum beta-lactamase producing E. coli 26 and sinus CT showed sinus mucosal thickening. He completed 10 days of remdesivir. 27 He received a 40 g (400 mg/kg) dose of IVIG on hospital day 9 with an increase in serum 28 IgG to 442 mg/mL on hospital day 12 but no significant changes in his clinical status. On 

Positive Outcome in a COVID-19 patient with Common Variable Immunodeficiency after IVIG

The clinical observation of a patient with common variable immunodeficiency diagnosed as having coronavirus disease 2019

A possible role for B cells in COVID-19? Lesson from patients with agammaglobulinemia

Features of 20 133 UK patients in hospital with covid-19 using the ISARIC WHO Clinical Characterisation Protocol: prospective observational cohort study

Currently available intravenous immunoglobulin contains antibodies reacting against severe acute respiratory syndrome coronavirus 2 antigens

Antibody against nucleocapsid protein predicts susceptibility to human coronavirus infection

High-Dose Intravenous Immunoglobulin as a Therapeutic Option for Deteriorating Patients With Coronavirus Disease

Profile of Immunoglobulin G and IgM Antibodies Against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)

Persistent detection of SARS-CoV-2 RNA in patients and healthcare workers with COVID-19

Effect of Convalescent Plasma Therapy on Viral Shedding and Survival in Patients With Coronavirus Disease